ArticleDiabetes care2013
Long-term changes in adiposity and glycemic control are associated with past adenovirus infection.
Article in Diabetes care, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Adenovirus 36 prevalence and association with human obesity: a systematic review.International journal of obesity (2005) · 2021Pooled it
- Pooled it
- Adenovirus 36 attenuates weight loss from exercise but improves glycemic control by increasing mitochondrial activity in the liver.PloS one · 2014Trial
- Human Adenovirus 36 Antibodies in Horses with Different Metabolic Statuses.Animals : an open access journal from MDPI · 2025Article
- Article
- Observational
- The human adenovirus PI3K-Akt activator E4orf1 is targeted by the tumor suppressor p53.Journal of virology · 2024Article
- Article
- Modulating effect of vitamin D status on serum anti-adenovirus 36 antibody amount in children with obesity: National Food and Nutrition Surveillance.BMC pediatrics · 2020Article
- What we know and what we need to know about adenovirus 36-induced obesity.International journal of obesity (2005) · 2020Review
- Obesity and Diabetes in an Arab population: Role of Adenovirus 36 Infection.Scientific reports · 2020Article
- Adenovirus 36 seropositivity is related to obesity risk, glycemic control, and leptin levels in Chilean subjects.International journal of obesity (2005) · 2020Article
- Ileal transcriptome analysis in obese rats induced by high-fat diets and an adenoviral infection.International journal of obesity (2005) · 2019Article
- Performing different kinds of physical exercise differentially attenuates the genetic effects on obesity measures: Evidence from 18,424 Taiwan Biobank participants.PLoS genetics · 2019Article
- HIV Persistence in Adipose Tissue Reservoirs.Current HIV/AIDS reports · 2018Review
- Viral Infections and Obesity.Current obesity reports · 2017Review
- Hepatic Expression of Adenovirus 36 E4ORF1 Improves Glycemic Control and Promotes Glucose Metabolism Through AKT Activation.Diabetes · 2017Article
- Adenovirus 36 antibody detection: Improving the standard serum neutralization assay.Journal of virological methods · 2017Article
- Infectious and Environmental Influences on the Obesity Epidemic.Current obesity reports · 2016Review
- An adenovirus-derived protein: A novel candidate for anti-diabetic drug development.Biochimie · 2016Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
objectiveAd36, a human adenovirus, increases adiposity but improves glycemic control in animal models. Similarly, natural Ad36 infection is cross-sectionally associated with greater adiposity and better glycemic control in humans. This study compared longitudinal observations in indices of adiposity (BMI and body fat percentage) and glycemic control (fasting glucose and insulin) in Ad36-infected versus uninfected adults. RESEARCH DESIGN AND
methodsBaseline sera from Hispanic men and women (n = 1,400) were screened post hoc for the presence of Ad36-specific antibodies. Indices of adiposity and glycemic control at baseline and at ~10 years past the baseline were compared between seropositive and seronegative subjects, with adjustment for age and sex. In addition to age and sex, indices of glycemic control were adjusted for baseline BMI and were analyzed only for nondiabetic subjects.
resultsSeropositive subjects (14.5%) had greater adiposity at baseline, compared with seronegative subjects. Longitudinally, seropositive subjects showed greater adiposity indices but lower fasting insulin levels. Subgroup analyses revealed that Ad36-seropositivity was associated with better baseline glycemic control and lower fasting insulin levels over time in the normal-weight group (BMI ≤25 kg/m(2)) and longitudinally, with greater adiposity in the overweight (BMI 25-30 kg/m(2)) and obese (BMI >30 kg/m(2)) men. Statistically, the differences between seropositive and seronegative individuals were modest in light of the multiple tests performed.
conclusionsThis study strengthens the plausibility that in humans, Ad36 increases adiposity and attenuates deterioration of glycemic control. Panoptically, the study raises the possibility that certain infections may modulate obesity or diabetes risk. A comprehensive understanding of these under-recognized factors is needed to effectively combat such metabolic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.